Comparison of the clinical features and clinical course of antimitochondrial antibody-positive and -negative primary biliary cirrhosis

Pietro Invernizzi, Andrea Crosignani, Pier Maria Battezzati, Giovanni Covini, Guya De Valle, Alberto Larchi, Massimo Zuin, Mauro Podda

Research output: Contribution to journalArticle

232 Citations (Scopus)

Abstract

Reports from North America and Northern Europe have suggested that antimitochondrial antibody (AMA) negative primary biliary cirrhosis (PBC) is a distinct chronic cholestatic liver disease with high prevalence of serum non-organ-specific autoantibodies other than AMA. To evaluate if such a peculiar serum immunoreactivity is associated with clinically relevant characteristics, we reviewed our experience with 297 Italian patients who have had a clinical and histological diagnosis of PBC and were regularly followed-up at our Center from June 1974 to June 1994. AMA-negative and AMA- positive patients were compared in terms of biochemical and clinical features, and clinical outcome of the disease. At presentation, 30 of 297 patients (10%) tested negative for AMA by indirect immunofluorescence. Six of them tested positive for antimitochondrial M2 antibodies (AMA-M2) by immunoblotting analysis, therefore, diagnosis of AMA-negative PBC was made in 24 patients (8%). At the initial visit, AMA-negative and AMA-positive patients were similar in terms of biochemical and clinical features. Antinuclear and anti-smooth-muscle antibodies (ANA and ASMA) were more frequently positive in the AMA-negative patients (71% vs. 31%, and 37% vs. 9%; both P = .0002). Incidence of complications of cirrhosis and development of liver failure resulting in death or referral for liver transplantation did not differ significantly between the two populations. In conclusion, data from this historical cohort study suggest that the distinct serological features of AMA-negative PBC are not associated with substantial differences in the clinical spectrum or course of the disease.

Original languageEnglish
Pages (from-to)1090-1095
Number of pages6
JournalHepatology
Volume25
Issue number5
Publication statusPublished - 1997

Fingerprint

Biliary Liver Cirrhosis
Antibodies
Liver Failure
Indirect Fluorescent Antibody Technique
North America
Serum
Immunoblotting
Liver Transplantation
Autoantibodies
Smooth Muscle
Liver Diseases
Fibrosis
Cohort Studies
Referral and Consultation

ASJC Scopus subject areas

  • Hepatology

Cite this

Comparison of the clinical features and clinical course of antimitochondrial antibody-positive and -negative primary biliary cirrhosis. / Invernizzi, Pietro; Crosignani, Andrea; Battezzati, Pier Maria; Covini, Giovanni; De Valle, Guya; Larchi, Alberto; Zuin, Massimo; Podda, Mauro.

In: Hepatology, Vol. 25, No. 5, 1997, p. 1090-1095.

Research output: Contribution to journalArticle

Invernizzi, Pietro ; Crosignani, Andrea ; Battezzati, Pier Maria ; Covini, Giovanni ; De Valle, Guya ; Larchi, Alberto ; Zuin, Massimo ; Podda, Mauro. / Comparison of the clinical features and clinical course of antimitochondrial antibody-positive and -negative primary biliary cirrhosis. In: Hepatology. 1997 ; Vol. 25, No. 5. pp. 1090-1095.
@article{624c8e343f244464b0be4d60b790e595,
title = "Comparison of the clinical features and clinical course of antimitochondrial antibody-positive and -negative primary biliary cirrhosis",
abstract = "Reports from North America and Northern Europe have suggested that antimitochondrial antibody (AMA) negative primary biliary cirrhosis (PBC) is a distinct chronic cholestatic liver disease with high prevalence of serum non-organ-specific autoantibodies other than AMA. To evaluate if such a peculiar serum immunoreactivity is associated with clinically relevant characteristics, we reviewed our experience with 297 Italian patients who have had a clinical and histological diagnosis of PBC and were regularly followed-up at our Center from June 1974 to June 1994. AMA-negative and AMA- positive patients were compared in terms of biochemical and clinical features, and clinical outcome of the disease. At presentation, 30 of 297 patients (10{\%}) tested negative for AMA by indirect immunofluorescence. Six of them tested positive for antimitochondrial M2 antibodies (AMA-M2) by immunoblotting analysis, therefore, diagnosis of AMA-negative PBC was made in 24 patients (8{\%}). At the initial visit, AMA-negative and AMA-positive patients were similar in terms of biochemical and clinical features. Antinuclear and anti-smooth-muscle antibodies (ANA and ASMA) were more frequently positive in the AMA-negative patients (71{\%} vs. 31{\%}, and 37{\%} vs. 9{\%}; both P = .0002). Incidence of complications of cirrhosis and development of liver failure resulting in death or referral for liver transplantation did not differ significantly between the two populations. In conclusion, data from this historical cohort study suggest that the distinct serological features of AMA-negative PBC are not associated with substantial differences in the clinical spectrum or course of the disease.",
author = "Pietro Invernizzi and Andrea Crosignani and Battezzati, {Pier Maria} and Giovanni Covini and {De Valle}, Guya and Alberto Larchi and Massimo Zuin and Mauro Podda",
year = "1997",
language = "English",
volume = "25",
pages = "1090--1095",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Inc.",
number = "5",

}

TY - JOUR

T1 - Comparison of the clinical features and clinical course of antimitochondrial antibody-positive and -negative primary biliary cirrhosis

AU - Invernizzi, Pietro

AU - Crosignani, Andrea

AU - Battezzati, Pier Maria

AU - Covini, Giovanni

AU - De Valle, Guya

AU - Larchi, Alberto

AU - Zuin, Massimo

AU - Podda, Mauro

PY - 1997

Y1 - 1997

N2 - Reports from North America and Northern Europe have suggested that antimitochondrial antibody (AMA) negative primary biliary cirrhosis (PBC) is a distinct chronic cholestatic liver disease with high prevalence of serum non-organ-specific autoantibodies other than AMA. To evaluate if such a peculiar serum immunoreactivity is associated with clinically relevant characteristics, we reviewed our experience with 297 Italian patients who have had a clinical and histological diagnosis of PBC and were regularly followed-up at our Center from June 1974 to June 1994. AMA-negative and AMA- positive patients were compared in terms of biochemical and clinical features, and clinical outcome of the disease. At presentation, 30 of 297 patients (10%) tested negative for AMA by indirect immunofluorescence. Six of them tested positive for antimitochondrial M2 antibodies (AMA-M2) by immunoblotting analysis, therefore, diagnosis of AMA-negative PBC was made in 24 patients (8%). At the initial visit, AMA-negative and AMA-positive patients were similar in terms of biochemical and clinical features. Antinuclear and anti-smooth-muscle antibodies (ANA and ASMA) were more frequently positive in the AMA-negative patients (71% vs. 31%, and 37% vs. 9%; both P = .0002). Incidence of complications of cirrhosis and development of liver failure resulting in death or referral for liver transplantation did not differ significantly between the two populations. In conclusion, data from this historical cohort study suggest that the distinct serological features of AMA-negative PBC are not associated with substantial differences in the clinical spectrum or course of the disease.

AB - Reports from North America and Northern Europe have suggested that antimitochondrial antibody (AMA) negative primary biliary cirrhosis (PBC) is a distinct chronic cholestatic liver disease with high prevalence of serum non-organ-specific autoantibodies other than AMA. To evaluate if such a peculiar serum immunoreactivity is associated with clinically relevant characteristics, we reviewed our experience with 297 Italian patients who have had a clinical and histological diagnosis of PBC and were regularly followed-up at our Center from June 1974 to June 1994. AMA-negative and AMA- positive patients were compared in terms of biochemical and clinical features, and clinical outcome of the disease. At presentation, 30 of 297 patients (10%) tested negative for AMA by indirect immunofluorescence. Six of them tested positive for antimitochondrial M2 antibodies (AMA-M2) by immunoblotting analysis, therefore, diagnosis of AMA-negative PBC was made in 24 patients (8%). At the initial visit, AMA-negative and AMA-positive patients were similar in terms of biochemical and clinical features. Antinuclear and anti-smooth-muscle antibodies (ANA and ASMA) were more frequently positive in the AMA-negative patients (71% vs. 31%, and 37% vs. 9%; both P = .0002). Incidence of complications of cirrhosis and development of liver failure resulting in death or referral for liver transplantation did not differ significantly between the two populations. In conclusion, data from this historical cohort study suggest that the distinct serological features of AMA-negative PBC are not associated with substantial differences in the clinical spectrum or course of the disease.

UR - http://www.scopus.com/inward/record.url?scp=0030948796&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030948796&partnerID=8YFLogxK

M3 - Article

VL - 25

SP - 1090

EP - 1095

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 5

ER -